Structure Therapeutics (NASDAQ:GPCR) Trading Down 5%

Structure Therapeutics Inc. (NASDAQ:GPCR)’s stock price traded down 5% on Monday . The company traded as low as $38.50 and last traded at $38.79. 110,941 shares traded hands during trading, a decline of 86% from the average session volume of 787,334 shares. The stock had previously closed at $40.84.

Wall Street Analyst Weigh In

Several research analysts recently commented on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $65.00 price objective on shares of Structure Therapeutics in a report on Monday. JPMorgan Chase & Co. started coverage on shares of Structure Therapeutics in a report on Tuesday, May 21st. They issued an “overweight” rating and a $65.00 price target on the stock. BMO Capital Markets boosted their price objective on shares of Structure Therapeutics from $83.00 to $100.00 and gave the company an “outperform” rating in a research note on Friday, June 7th. Finally, JMP Securities cut their price target on shares of Structure Therapeutics from $91.00 to $86.00 and set a “market outperform” rating for the company in a report on Friday, August 9th. Seven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Structure Therapeutics has a consensus rating of “Buy” and a consensus target price of $84.63.

Structure Therapeutics Trading Down 1.1 %

The firm has a fifty day moving average of $38.12 and a two-hundred day moving average of $39.67. The company has a market capitalization of $1.88 billion, a PE ratio of -50.66 and a beta of -3.52.

Structure Therapeutics (NASDAQ:GPCR) last issued its earnings results on Thursday, August 8th. The company reported ($0.18) EPS for the quarter, topping the consensus estimate of ($0.23) by $0.05. On average, equities analysts expect that Structure Therapeutics Inc. will post -0.86 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the business. Boxer Capital LLC bought a new stake in shares of Structure Therapeutics in the 4th quarter worth approximately $16,304,000. Avoro Capital Advisors LLC raised its holdings in Structure Therapeutics by 133.3% in the 4th quarter. Avoro Capital Advisors LLC now owns 2,333,333 shares of the company’s stock worth $95,107,000 after purchasing an additional 1,333,333 shares in the last quarter. Octagon Capital Advisors LP purchased a new stake in shares of Structure Therapeutics in the 4th quarter worth about $16,875,000. Bellevue Group AG boosted its stake in shares of Structure Therapeutics by 2,858.7% during the 1st quarter. Bellevue Group AG now owns 363,926 shares of the company’s stock valued at $15,598,000 after purchasing an additional 351,626 shares in the last quarter. Finally, Capital International Investors purchased a new position in shares of Structure Therapeutics during the fourth quarter valued at about $34,647,000. Hedge funds and other institutional investors own 91.78% of the company’s stock.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.